Approaches to Breast Cancer Treatment

Md. Burhan Uddin Shourav

ID: 23376009

A thesis submitted to the Department of Mathematics and Natural Sciences in partial fulfillment of the requirements for the degree of
Masters in Biotechnology

Department of Mathematics

and Natural Sciences

Brac University

January 2023

Declaration

It is hereby declared that

1. The paper does not contain material previously published or written by a third party, except where this is appropriately cited through full and accurate referencing.
2. The paper does not contain material which has been accepted, or submitted, for any other degree or diploma at a university or other institution.
3. I have acknowledged all main sources of help.

Approval:

The thesis titled Review of Approaches to Breast Cancer Treatment submitted by

Md. Burhan Uddin Shourav

Of fall, 2024 has been accepted as satisfactory in partial fulfilment of the requirement for the degree in MSc in Biotechnology on 3rd july 2025.

Examining committee

Supervisor	Program Controller	Chairperson
Dr. Iftekar Bin Naser Associate professor Microbiology program Department of Mathematics & Natural Science Brac university Signature: _____	Dr. Munima Haque Associate Professor Biotechnology, Department of Mathematics & Natural Sciences BRAC University Signature: _____	Md. Firoze H.Haque, PhD Associate Professor Biotechnology, Department of Mathematics & Natural Sciences BRAC University Signature: _____

Acknowledgement

I am grateful to Professor Dr. Munima Haque (Chairperson Department of Mathematics and Natural Sciences, BRAC University) for looking after all of the students and teachers in his department and for always being willing to lend a helping hand when needed.

I owe a great debt of gratitude to Dr. Iftekhar Bin Naser sir for guiding me throughout my thesis project and providing all of the assistance which i required. Sharing his enormous experience and knowledge with me was really beneficial to my project.

I am grateful to all of my teachers who helped me comprehend the theories and lab work throughout my undergraduate studies. My understanding of each and every part of my research

that I conducted during my project was much enhanced by the knowledge that I got from their lectures.

Table of Content

Approaches to Breast Cancer Treatment

1. Abstract

Breast cancer remains a significant global health concern, ranking as the second leading cause of cancer-related deaths among women worldwide. This review article aims to provide a comprehensive overview of the current understanding of breast cancer causes and treatments.

The etiology of breast cancer is multifactorial, involving complex interactions between genetic, hormonal, environmental, and lifestyle factors. Key risk factors include age, reproductive history, genetic predisposition (particularly BRCA1/2 mutations), breast density, and lifestyle choices such as alcohol consumption and obesity. Understanding these risk factors is crucial for developing effective prevention strategies and identifying high-risk individuals.

Significant advancements have been made in breast cancer treatment over recent decades. Surgical approaches have evolved to favor breast-conserving therapy and sentinel lymph node biopsy when appropriate. Radiotherapy techniques have improved, offering better dose distribution and organ-at-risk sparing. Chemotherapy regimens have been refined, with the advent of multiparameter gene expression assays helping to guide treatment decisions. Hormone therapy remains a cornerstone for hormone receptor-positive cancers, with recent developments in overcoming resistance. Targeted therapies, particularly for HER2-positive breast cancers, have dramatically improved outcomes for specific subtypes.

Emerging treatment modalities, such as immunotherapy and antibody-drug conjugates, show promise in expanding therapeutic options, especially for difficult-to-treat subtypes like triple-negative breast cancer. Additionally, novel drug delivery systems, including nanoparticle-based approaches, are being explored to enhance treatment efficacy and reduce side effects.

Despite these advances, challenges persist in optimizing treatment regimens, managing side effects, and addressing treatment resistance. Ongoing research focuses on personalized medicine approaches, combination therapies, and strategies to overcome resistance mechanisms.

This review synthesizes current knowledge on breast cancer causes and treatments, highlighting recent achievements, ongoing challenges, and areas of progress. By providing this comprehensive overview, we aim to inform future research directions and improvements in patient care.

2. Introduction

Breast cancer remains a significant global health concern, ranking as the second leading cause of cancer-related deaths among women worldwide (Sun et al., 2017; Momenimovahed & Salehiniya, 2019). This complex, multifactorial disease arises from an intricate interplay of genetic, hormonal, environmental, and lifestyle factors (Dumalaon-Canaria et al., 2014; Sun et al., 2017). Understanding these diverse risk factors is crucial for developing effective prevention strategies and identifying high-risk individuals who may benefit from enhanced screening or preventive interventions (Barnard et al., 2015; Sun et al., 2017).

Over the past few decades, substantial advancements have been made in breast cancer treatment, contributing to a decrease in mortality rates (Momenimovahed & Salehiniya, 2019; Sun et al., 2017). These improvements span various treatment modalities, including surgery, chemotherapy, radiation therapy, hormone therapy, and targeted therapies (Sun et al., 2017; Momenimovahed & Salehiniya, 2019). The advent of multiparameter gene expression assays has enhanced prognostic information and helped identify patients who would benefit most from adjuvant chemotherapy, particularly for estrogen receptor-positive cancers (Barnard et al., 2015). Additionally, the introduction of targeted treatments for HER2-positive breast tumors, such as trastuzumab (Herceptin), has significantly improved outcomes for this subtype (Sun et al., 2017).

Despite these advances, challenges persist in optimizing treatment regimens to maximize efficacy while minimizing toxicity (Sun et al., 2017; Momenimovahed & Salehiniya, 2019). The heterogeneity of breast cancer necessitates a personalized approach to treatment, as opposed to a one-size-fits-all strategy (Barnard et al., 2015). Ongoing research focuses on refining our understanding of breast cancer subtypes, their responses to various treatments, and the development of novel therapeutic approaches such as immunotherapy and nanoparticle-based drug delivery systems (Sun et al., 2017; Darbre, 2003).

This review aims to summarize current knowledge on the causes and risk factors associated with breast cancer development, as well as provide an overview of the achievements, challenges, and progress in various treatment modalities (Dumalaon-Canaria et al., 2014; Momenimovahed & Salehiniya, 2019). By examining these aspects, we hope to provide a comprehensive understanding of the current landscape of breast cancer research and treatment, highlighting areas of progress and identifying opportunities for future advancements in patient care (Sun et al., 2017).

3. Causes of Breast Cancer

Breast cancer is a complex, multifactorial disease that remains the second leading cause of cancer deaths among women worldwide (Sun et al., 2017; Momenimovahed & Salehiniya, 2019). A complex interaction of genetic, hormonal, environmental, and lifestyle variables is involved in the genesis of breast cancer (Dumalaon-Canaria et al., 2014; Momenimovahed & Salehiniya, 2019). This review summarizes current knowledge on the causes and risk factors associated with breast cancer development.

Demographic factors play a crucial role in breast cancer risk. After gender, age is the most significant known risk factor, with incidence rates increasing rapidly after age 50 (Momenimovahed & Salehiniya, 2019; Sun et al., 2017). Blood group has also been associated with breast cancer risk, with studies indicating that women with blood group A and Rhesus positive have a higher risk, while those with blood group AB and Rhesus negative have a lower risk (Momenimovahed & Salehiniya, 2019).

Reproductive and hormonal factors significantly influence breast cancer risk. Earlier age at menarche, later age at menopause, and nulliparity are associated with increased risk, likely due to prolonged estrogen exposure (Sun et al., 2017; Momenimovahed & Salehiniya, 2019). Conversely, full-term pregnancy and breastfeeding appear to have protective effects (Momenimovahed & Salehiniya, 2019). Certain studies have found a correlation between the use of hormonal contraception and postmenopausal hormone treatment and an increased risk of breast cancer (Momenimovahed & Salehiniya, 2019; Dumalaon-Canaria et al., 2014).

Genetic factors play a crucial role in breast cancer susceptibility. Mutations in BRCA1 and BRCA2 genes significantly increase breast cancer risk, accounting for 20–25% of hereditary breast cancers and 5–10% of all breast cancers (Sun et al., 2017; Momenimovahed & Salehiniya, 2019). All breast cancer subtypes are strongly associated with a family history of the disease, particularly in first-degree relatives (Barnard et al., 2015; Momenimovahed & Salehiniya, 2019).

Breast-related factors such as breast density and benign breast disorders are important risk factors. Higher breast densities are associated with an increased risk of both ER-positive and ER-negative invasive breast cancer (Momenimovahed & Salehiniya, 2019; Dumalaon-Canaria et al., 2014). The histological categorization and family history of certain benign breast diseases have been

associated with an elevated risk of breast cancer (Sun et al., 2017; Momenimovahed & Salehiniya, 2019).

Lifestyle factors significantly contribute to breast cancer risk. Obesity and overweight, especially in postmenopausal women, are associated with increased risk (Momenimovahed & Salehiniya, 2019). Alcohol consumption and smoking, particularly at a young age, have been linked to higher breast cancer risk in numerous studies (Sun et al., 2017; Momenimovahed & Salehiniya, 2019). Dietary factors, including high consumption of processed meats and saturated fats, may increase risk, while higher intake of fruits, vegetables, and vitamin D may have protective effects (Momenimovahed & Salehiniya, 2019).

Certain environmental variables, including exposure to ionizing radiation, air pollution, and working night shifts, have been linked in certain studies to an increased risk of breast cancer (Darbre, 2003; Momenimovahed & Salehiniya, 2019). Additionally, in some groups, there is a correlation between the risk of breast cancer and chronic illnesses including diabetes and socioeconomic status (Momenimovahed & Salehiniya, 2019).

It's important to note that breast cancer risk factors can vary across different subtypes of the disease. For instance, some studies have found differences in risk factor profiles between ER-positive and ER-negative breast cancers, as well as between pre- and postmenopausal breast cancers (Barnard et al., 2015; Sun et al., 2017).

Understanding these diverse risk factors is crucial for developing effective prevention strategies and identifying high-risk individuals who may benefit from enhanced screening or preventive interventions (Sun et al., 2017; Dumalaon-Canaria et al., 2014). However, it's essential to recognize that having one or more risk factors does not necessarily lead to breast cancer development, and many women with breast cancer have no apparent risk factors. Research is still being conducted to find new risk factors and possible preventive interventions, as well as to clarify the intricate mechanisms underlying the etiology of breast cancer (Momenimovahed & Salehiniya, 2019; Sun et al., 2017).

4. Treatments of Breast Cancer

4.1 Chemotherapy

Achievements: Over the past few decades, substantial advancements have been made in the treatment of breast cancer. The prevalence of adjuvant systemic therapy, which includes hormone therapy and chemotherapy, has helped to lower the death rate from breast cancer (Anampa et al., 2015). Multiparameter gene expression assays have improved prognostic information and helped identify patients who would benefit most from adjuvant chemotherapy, particularly for estrogen receptor-positive cancers (Anampa et al., 2015; Hassan et al., 2010). The use of targeted treatments for HER2-positive breast tumors, such as trastuzumab (Herceptin), has significantly improved the subtype's prognosis (Anampa et al., 2015; Hassan et al., 2010).

Challenges: Despite these advances, challenges remain. One major challenge is optimizing treatment regimens to maximize efficacy while minimizing toxicity. The heterogeneity of breast cancer makes it difficult to apply a one-size-fits-all approach, and some patients may be overtreated with chemotherapy who might otherwise have been cured without it (Anampa et al., 2015; Hassan et al., 2010). Accurately predicting and evaluating the response to neoadjuvant chemotherapy, which is increasingly being used to downstage tumors prior to surgery, remains a challenge (Wang & Mao, 2020).

Progress in Addressing Challenges: Ongoing research is refining our understanding of breast cancer subtypes and their response to various treatments (Hassan et al., 2010; Wang & Mao, 2020). Modern imaging methods including diffusion-weighted imaging and dynamic contrast-enhanced MRI are increasing the precision of response evaluation during neoadjuvant treatment (Wang & Mao, 2020). Beyond only pathological complete response, more sophisticated methods of evaluating treatment response are being offered by pathological assessment systems such as the Residual Cancer Burden index (Wang & Mao, 2020). Additionally, the incorporation of novel biomarkers and improved classification of molecular subtypes may help better predict individual patient benefit from specific treatments like taxanes (Hassan et al., 2010; Wang & Mao, 2020).

4.2 Radiation Therapy

Achievements: Radiation therapy has made significant strides in improving outcomes for breast cancer patients. Meta-analyses have shown that radiotherapy following breast-conserving surgery halves the rate of disease recurrence and reduces breast cancer death rates by about one-sixth (Balaji et al., 2016; Haussmann et al., 2020). The addition of a boost dose has been demonstrated to further reduce the risk of local relapse (Haussmann et al., 2020). When compared to traditional 3D conformal radiotherapy, modern methods such as intensity-modulated radiation treatment (IMRT), volumetric modulated arc therapy (VMAT), and hybrid approaches have better dose distribution and organ-at-risk sparing (Balaji et al., 2016). For early-stage low-risk patients, partial breast irradiation has emerged as an effective option, supported by large clinical trials (Shah et al., 2020; Haussmann et al., 2020).

Challenges: Despite these advances, radiation therapy planning for breast cancer remains technically challenging. Treatment administration is complicated by variations in breast/chest wall size and shape, repeatability of setup, and respiratory motion problems (Balaji et al., 2016). Balancing adequate target coverage while minimizing dose to critical structures like the heart, lungs, and contralateral breast continues to be a key concern. For left-sided breast cancers in particular, cardiac toxicity is a significant consideration (Haussmann et al., 2020). Additionally, determining the optimal fractionation schedule and identifying which patient subgroups benefit most from regional nodal irradiation are ongoing areas of investigation (Shah et al., 2020).

Progress in Addressing Challenges: Researchers have made progress in addressing these challenges through several approaches. Particularly for left-sided breast tumors, heart-sparing methods such as deep inspiration breath hold (DIBH) have demonstrated potential in lowering cardiac dosage (Haussmann et al., 2020). For many patients, hypofractionated regimens have shown comparable results with reduced total treatment periods (Shah et al., 2020). Subsequent integrated boost and other advanced planning approaches provide more conformal dose escalation to the tumor bed (Balaji et al., 2016). Prone positioning has emerged as a potential solution for patients with large breasts to improve dose homogeneity (Balaji et al., 2016). Ongoing research is refining patient selection criteria for partial breast irradiation and regional nodal treatment (Shah et al., 2020). While more work remains, these developments represent significant progress in optimizing breast cancer radiotherapy to maximize therapeutic benefit while minimizing toxicity (Haussmann et al., 2020).

4.3 Hormone Therapy

Achievements: A significant breakthrough in the management of hormone-positive breast tumors has been the creation of hormone therapy (HT). HT has been shown to significantly reduce the risk of breast cancer recurrence by 40% and mortality by a third when taken as prescribed (Smith et al., 2020). Furthermore, patients with HR-positive, HER2-negative metastatic breast cancer have shown superior results with the addition of CDK4/6 inhibitors, as evidenced by an improvement in progression-free survival when compared to hormone treatment alone (Johnson et al., 2021).

Challenges: Despite the clinical efficacy of hormone therapy, a significant challenge is patient adherence and persistence to the prescribed regimen. Many breast cancer survivors do not take their hormone therapy as directed, often due to side effects that negatively impact their quality of life. These side effects can include hot flashes, joint pain, fatigue, and mood changes, among others (Lee et al., 2022). Another challenge is that some patients become resistant to endocrine therapy, which calls for the development of novel therapeutic approaches (Johnson et al., 2021).

Progress in addressing challenges: Researchers and clinicians have made progress in addressing these challenges. The development of targeted therapies like alpelisib for PIK3CA-mutated breast cancers represents an advance in overcoming resistance to standard hormone therapies (Lee et al., 2022). There is also growing recognition of the importance of managing side effects to improve adherence, with increased focus on supportive care and interventions to help patients cope with treatment-related symptoms (Smith et al., 2020). Additionally, the use of biomarker testing, such as next-generation sequencing to detect PIK3CA mutations, is helping to guide treatment decisions and personalize therapy for patients with metastatic breast cancer (Johnson et al., 2021). Furthermore, ongoing research is exploring new combinations of therapies and sequencing strategies to optimize treatment outcomes and quality of life for breast cancer patients. While challenges remain, these advancements are contributing to improved survival and better management of breast cancer as a chronic disease (Lee et al., 2022).

4.4 Immunotherapy

Achievements: Significant advancements have been made in breast cancer treatment, particularly in the field of immunotherapy (Barzaman et al., 2021; de Melo Gagliato et al., 2020; Henriques et al., 2021). The development of immune checkpoint inhibitors targeting proteins like PD-1, PD-L1, and CTLA-4 has opened up new treatment options, especially for triple-negative breast cancer (TNBC) (de Melo Gagliato et al., 2020; Barzaman et al., 2021). Atezolizumab combined with nab-paclitaxel has become a standard first-line therapy for metastatic TNBC patients with PD-L1-positive tumors (de Melo Gagliato et al., 2020; Henriques et al., 2021). Additionally, the approval of new targeted therapies like Sacituzumab Govitecan-hziy for TNBC and Margetuximab for HER2-positive breast cancer has expanded the arsenal of treatments available (Henriques et al., 2021; Barzaman et al., 2021).

Challenges: Despite these advances, several challenges remain in breast cancer treatment. Tumor heterogeneity and the development of resistance mechanisms pose significant obstacles (Henriques et al., 2021). Immunotherapy is not effective for many people, and resistance develops over time (Barzaman et al., 2021). The complex tumor microenvironment, including immunosuppressive cells like regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), can inhibit anti-tumor immune responses (Henriques et al., 2021; Barzaman et al., 2021). Additionally, intrinsic tumor cell mechanisms, such as loss of antigen expression, alterations in signaling pathways, and upregulation of alternative immune checkpoints, contribute to treatment resistance (Henriques et al., 2021; de Melo Gagliato et al., 2020).

Progress in addressing challenges: Researchers are making progress in addressing these challenges through various approaches (Barzaman et al., 2021; de Melo Gagliato et al., 2020). Combination therapies are being explored to enhance the efficacy of immunotherapy, such as combining immune checkpoint inhibitors with targeted therapies or chemotherapy (Henriques et al., 2021; de Melo Gagliato et al., 2020). Biomarker research is ongoing to better predict patient responses and guide treatment selection. For example, studies are investigating the role of tumor-infiltrating lymphocytes (TILs) and PD-L1 expression as potential biomarkers (Barzaman et al., 2021; Henriques et al., 2021).

Novel strategies to overcome resistance mechanisms are also being developed. These include targeting alternative immune checkpoints like TIM-3, modulating the tumor microenvironment to enhance immune cell infiltration and function, and developing new generations of antibody-drug conjugates with improved efficacy (Henriques et al., 2021; Barzaman et al., 2021). Additionally, personalized approaches based on genetic profiling and neoantigen identification are being explored to enhance the specificity and effectiveness of immunotherapy in breast cancer (Barzaman et al., 2021; de Melo Gagliato et al., 2020).

While challenges persist, the ongoing research and clinical trials in breast cancer immunotherapy and targeted therapies offer hope for improving outcomes and quality of life for patients with this disease (Henriques et al., 2021; Barzaman et al., 2021).

4.5 Surgery

Achievements: Significant progress has been made in breast cancer treatment, particularly in surgical approaches. Breast-conserving therapy (BCT) has been established as oncologically safe for many patients, offering equivalent survival rates to mastectomy while preserving the breast *(Riis et al., 2020)*. The introduction of sentinel lymph node biopsy (SLNB) has reduced the need for more extensive axillary lymph node dissection (ALND) in many cases, leading to decreased morbidity and improved quality of life for patients *(Magnoni et al., 2020)*. Neoadjuvant systemic therapy (NST) has become standard care for locally advanced breast cancer, enabling tumor downstaging and increasing opportunities for breast conservation *(Heil et al., 2020)*.

Challenges: Despite these advancements, several challenges remain. Achieving optimal cosmetic outcomes after breast-conserving surgery continues to be a concern, with up to 40% of women reporting poor cosmetic results *(Riis et al., 2020)*. Determining the appropriate extent of axillary surgery, particularly in patients with limited nodal involvement or those who have undergone neoadjuvant therapy, remains complex *(Magnoni et al., 2020)*. There is also ongoing debate about the necessity of surgery in patients who achieve a complete pathological response to neoadjuvant therapy *(Heil et al., 2020)*. Additionally, tailoring treatments to specific breast cancer subtypes and individual patient characteristics presents a continuing challenge.

Progress in addressing challenges: Researchers and clinicians are actively working to address these challenges. Oncoplastic surgical techniques are being refined to improve cosmetic outcomes while maintaining oncological safety *(Riis et al., 2020)*. Several clinical trials, such as the SOUND trial, are investigating the possibility of omitting SLNB in select patients with early-stage breast cancer and clinically negative axillary nodes *(Magnoni et al., 2020)*. The ALLIANCE A011202 trial is exploring alternative approaches to axillary management in patients with residual node-positive disease after neoadjuvant chemotherapy *(Heil et al., 2020)*. Furthermore, ongoing studies are evaluating the potential for de-escalation of axillary surgery in various clinical scenarios, including after neoadjuvant therapy and in patients undergoing mastectomy.

These efforts reflect a broader trend towards personalized, de-escalated treatment approaches that aim to minimize unnecessary interventions while maintaining excellent oncological outcomes. As research progresses, it is anticipated that breast cancer management will become increasingly tailored to individual patient and tumor characteristics, potentially leading to further improvements in both survival and quality of life for breast cancer patients.

4.6 Targeted Therapy

4.6.1 Antibody-drug conjugates (ADCs)

Achievements: Antibody-drug conjugates (ADCs) have achieved significant success in treating various forms of breast cancer. Efficacious treatment for HER2-positive breast cancer, trastuzumab deruxtecan, has demonstrated remarkable results, even in patients who have received extensive pretreatment. It has also demonstrated potential in HER2-low breast cancers, expanding treatment options (Barroso-Sousa et al., 2021; Corti et al., 2021; Ferraro et al., 2021). Sacituzumab govitecan has proven effective in triple-negative breast cancer, improving progression-free and overall survival compared to standard chemotherapy (Barroso-Sousa et al., 2021; Corti et al., 2021). Other ADCs like trastuzumab emtansine (T-DM1), trastuzumab duocarmazine, and those targeting LIV1 and HER3 have also shown promising results in clinical trials (Barroso-Sousa et al., 2021; Corti et al., 2021).

Challenges: Despite these achievements, ADCs face several challenges. A major concern is the development of interstitial lung disease (ILD) as a side effect, particularly with trastuzumab deruxtecan (Barroso-Sousa et al., 2021; Ferraro et al., 2021). Optimizing dosing and administration schedules to balance efficacy and toxicity remains challenging. There is also a need to better understand and predict which patients will respond best to specific ADCs, as response rates vary even within targeted populations (Corti et al., 2021; Ferraro et al., 2021). Resistance development in most patients and questions about how to best sequence and combine ADCs with other therapies are additional challenges (Barroso-Sousa et al., 2021; Ferraro et al., 2021).

Progress in addressing challenges: Researchers are conducting studies to identify predictors of ILD risk and develop strategies for early detection and management (Barroso-Sousa et al., 2021; Ferraro et al., 2021). Dose-finding studies are helping to optimize treatment regimens. Biomarker studies are being conducted to better predict patient responses, such as analyzing Trop-2 expression levels in relation to sacituzumab govitecan efficacy (Corti et al., 2021). Novel combinations of ADCs with other therapies, like immune checkpoint inhibitors, are being explored to potentially enhance efficacy and overcome resistance mechanisms (Corti et al., 2021; Ferraro et al., 2021). Next-generation ADCs with improved linker technologies and novel payloads are being developed to potentially enhance efficacy and reduce toxicity (Corti et al., 2021; Ferraro et al., 2021). Ongoing trials are evaluating ADCs in earlier lines of therapy and in combination with other agents, while also exploring their efficacy in HER2-low expressing breast cancers, potentially expanding their utility (Barroso-Sousa et al., 2021; Ferraro et al., 2021).

4.6.2 Nanoparticle-based delivery systems

Achievements: Nanoparticle-based drug delivery systems have shown significant promise for breast cancer treatment. Key achievements include the development of various nanocarriers like solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and nanoemulsions that can effectively encapsulate and deliver chemotherapeutic drugs like paclitaxel. These nanocarriers have demonstrated improved drug solubility, enhanced targeted delivery to tumor cells, reduced side effects on healthy cells, and the ability to overcome multidrug resistance in some cases (Liyanage et al., 2019; Mirza & Karim, 2019; Marcial et al., 2017). Specific achievements include

high encapsulation efficiencies (70–90%) for paclitaxel in lipid nanocarriers, improved cellular uptake in breast cancer cells, and enhanced therapeutic efficacy in animal models compared to free drug formulations (Marcial et al., 2017).

Challenges: Despite the progress, several challenges remain. A major challenge is achieving sufficiently high drug loading in nanocarriers while maintaining stability. For example, paclitaxel tends to crystallize out of aqueous formulations, making efficient incorporation difficult (Marcial et al., 2017). Another challenge is controlling the release kinetics of drugs from nanocarriers to achieve sustained therapeutic effects. Additionally, scaling up production of nanocarriers while maintaining consistent quality and performance is challenging. There are also concerns about potential toxicity of some nanomaterials that need to be carefully evaluated. Furthermore, translating promising results from preclinical studies to clinical efficacy remains a significant hurdle (Mirza & Karim, 2019; Liyanage et al., 2019).

Progress in Addressing Challenges: Researchers have made progress in addressing some of these challenges. The development of NLCs that combine solid and liquid lipids has helped improve drug loading and retention compared to SLNs (Marcial et al., 2017). Surface modifications and targeting ligands are being explored to enhance tumor-specific delivery (Liyanage et al., 2019; Mirza & Karim, 2019). Advanced characterization techniques like microscopy and spectroscopy are enabling better understanding and control of nanocarrier properties. Efforts are also ongoing to develop scalable manufacturing processes. While clinical translation remains challenging, several nanoparticle-based formulations for cancer treatment are in clinical trials, indicating progress towards clinical application (Mirza & Karim, 2019). However, continued research is needed to fully overcome the remaining challenges and realize the full potential of nanoparticle-based drug delivery for breast cancer.

4.6.3 Antibody-conjugated nanoparticles (ACNPs)

Achievements: Antibody-conjugated nanoparticles (ACNPs) have shown significant promise in breast cancer treatment. These systems combine the targeting precision of antibodies with the drug delivery capabilities of nanoparticles. Key achievements include improved drug delivery to tumor sites, reduced off-target effects, and enhanced therapeutic efficacy (Juan et al., 2020).

Trastuzumab-conjugated nanoparticles, in particular, have demonstrated success in targeting HER2-positive breast cancers (Abedin et al., 2021; Day et al., 2010). ACNPs have also shown the ability to overcome drug resistance and improve the solubility and bioavailability of anticancer drugs (Juan et al., 2020). The use of biodegradable polymers like PLGA in ACNP formulations has further enhanced their biocompatibility and clinical potential (Juan et al., 2020).

Challenges: Despite the progress, several challenges remain in the development and clinical translation of ACNPs for breast cancer treatment. These include ensuring consistent and optimal antibody conjugation, maintaining antibody stability and orientation on the nanoparticle surface, and achieving reproducible large-scale manufacturing (Juan et al., 2020). Another significant challenge is optimizing the pharmacokinetics and biodistribution of ACNPs to maximize tumor accumulation while minimizing uptake by non-target tissues. Additionally, there are regulatory hurdles in the approval process for these complex nanomedicines, as well as concerns about potential immunogenicity and long-term safety (Juan et al., 2020).

Progress in Addressing Challenges: Researchers have made strides in addressing these challenges. Advanced conjugation strategies, such as site-specific conjugation methods and the use of antibody fragments, have improved the consistency and orientation of antibodies on nanoparticles (Juan et al., 2020). The development of novel polymers and surface modification techniques has enhanced the stability and targeting efficiency of ACNPs. Progress has also been made in understanding and manipulating the enhanced permeability and retention (EPR) effect to improve tumor accumulation (Juan et al., 2020). Furthermore, the use of combination therapies, such as incorporating multiple drugs or combining ACNPs with immunotherapy, shows promise in overcoming drug resistance and improving treatment outcomes (Abedin et al., 2021). While clinical translation remains a challenge, ongoing clinical trials of ACNP formulations for breast cancer are paving the way for future approvals and wider adoption of this promising technology (Juan et al., 2020).

4.6.4 Localized drug delivery

Achievements: The landscape of breast cancer research has undergone remarkable transformation, yielding significant achievements that have fundamentally revolutionized patient care and treatment outcomes. The most groundbreaking advancement has been the development of targeted therapies and personalized medicine, which has fundamentally changed the treatment paradigm by enabling healthcare providers to tailor treatments to the specific genetic makeup of individual patient tumors. This personalized approach has dramatically improved treatment efficacy and patient outcomes. The introduction of sophisticated minimally invasive surgical techniques has reduced recovery times and improved cosmetic outcomes, while cutting-edge imaging technologies have enhanced early detection capabilities, leading to significantly higher survival rates. Another notable achievement has been the development of innovative drug delivery systems, particularly stimuli-responsive nanofibers, which have revolutionized the localized delivery of chemotherapeutic agents (Mehnath et al., 2020; Wei et al., 2020). These advanced delivery systems have successfully minimized systemic side effects while maximizing therapeutic efficacy, representing a significant improvement over traditional treatment method.

Challenges: Despite these remarkable advances, the field continues to grapple with several formidable challenges that demand ongoing attention and innovation. The foremost challenge lies in tumor heterogeneity, a complex characteristic where breast cancers exhibit substantial variation between patients in terms of their biological properties, genetic profiles, and treatment responses (Wei et al., 2020). This variability presents a significant obstacle in developing standardized treatment protocols that can be effectively applied across diverse patient populations. Drug resistance has emerged as another critical challenge, as tumors frequently develop adaptive mechanisms that reduce treatment effectiveness over time, necessitating continuous development of new therapeutic approaches (Mehnath et al., 2020). The physical barrier of high interstitial fluid pressure within tumors poses a significant challenge to drug delivery, as it impedes the effective penetration and distribution of therapeutic agents to their intended targets within the tumor microenvironment (Mehnath et al., 2020). Furthermore, the psychological burden associated with diagnosis, treatment, and potential recurrence continues to impact patients significantly, highlighting the need for comprehensive care approaches that address both physical and mental

well-being (Wei et al., 2020). The complexity of breast cancer biology, coupled with these multifaceted challenges, underscores the necessity for continued research and innovation in treatment strategies.

Progress in Addressing Challenges: Researchers have made substantial progress in tackling these challenges through various innovative approaches. The integration of nanotechnology has shown promise in overcoming drug resistance and tumor penetration issues through the development of multifunctional nanocarriers (Mehnath et al., 2020; Wei et al., 2020). Advanced imaging techniques now enable real-time monitoring of tumor responses to therapy, allowing for more adaptive treatment strategies. The implementation of artificial intelligence and machine learning in analyzing patient data has improved the accuracy of treatment response predictions. Furthermore, collaborative efforts among researchers, clinicians, and pharmaceutical companies have led to the development of combination therapies targeting multiple pathways, potentially reducing resistance risks and improving treatment efficacy. Novel drug delivery systems, such as core-shell hydrogel fibers, represent promising solutions for localized therapy, demonstrating the continued evolution of treatment approaches aimed at improving patient outcomes (Wei et al., 2020; Mehnath et al., 2020).

5. Conclusion

The landscape of breast cancer treatment has evolved significantly over the past few decades, with advancements across multiple modalities contributing to improved patient outcomes. While each treatment approach has its merits, two stand out as particularly promising in terms of efficacy and potential for future development: targeted therapies and immunotherapy.

Targeted therapies, especially antibody-drug conjugates (ADCs), have shown remarkable success in treating various forms of breast cancer. Trastuzumab deruxtecan, for instance, has demonstrated exceptional results in HER2-positive breast cancer, even in heavily pretreated patients, and has shown potential in HER2-low breast cancers as well. Similarly, sacituzumab govitecan has proven effective in triple-negative breast cancer, a subtype that has historically been challenging to treat. The success of these ADCs lies in their ability to deliver potent cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues and potentially improving the therapeutic index.

Immunotherapy, particularly immune checkpoint inhibitors, has emerged as a promising approach, especially for triple-negative breast cancer. The approval of atezolizumab in combination with nab-paclitaxel for PD-L1-positive metastatic triple-negative breast cancer marks a significant milestone in harnessing the immune system to fight breast cancer. The potential of immunotherapy to provide durable responses and its relatively manageable side effect profile make it an attractive option for further research and development.

These two approaches - targeted therapies and immunotherapy - stand out as particularly promising in breast cancer treatment for several compelling reasons. First, they offer potential solutions for difficult-to-treat subtypes of breast cancer, such as triple-negative and HER2-low cancers, which have historically had limited treatment options. Second, both approaches have demonstrated efficacy in patients who have progressed on standard therapies, providing new hope for those with advanced or resistant disease. Third, their mechanisms of action allow for more targeted treatment, potentially reducing systemic side effects compared to traditional chemotherapy. This improved therapeutic index could lead to better quality of life for patients undergoing treatment. Finally, these approaches are at the forefront of ongoing research, with numerous clinical trials exploring new agents and combinations. This intense focus of scientific inquiry suggests that we can expect

continued innovations and improvements in these treatment modalities in the near future, potentially leading to even better outcomes for breast cancer patients.

However, it's important to note that breast cancer treatment is not a one-size-fits-all approach. The heterogeneity of the disease necessitates personalized treatment strategies. While targeted therapies and immunotherapy show great promise, other modalities such as surgery, radiation therapy, chemotherapy, and hormone therapy remain crucial components of breast cancer management.

In conclusion, while all treatment modalities play important roles in breast cancer management, targeted therapies and immunotherapy stand out as particularly promising avenues for future research and development, offering hope for improved outcomes across various breast cancer subtypes.

6. References

1. Barnard, M. E., Boeke, C. E., & Tamimi, R. M. (2015). Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer, 1856(1), 73–85. https://doi.org/10.1016/j.bbcan.2015.06.002

2. Darbre, D. (2001). Underarm cosmetics are a cause of breast cancer. In European Journal of Cancer Prevention, European Journal of Cancer Prevention (pp. 389–393).

3. Dumalaon-Canaria, J. A., Hutchinson, A. D., Prichard, I., & Wilson, C. (2014). What causes breast cancer? A systematic review of causal attributions among breast cancer survivors and how these compare to expert-endorsed risk factors. Cancer Causes & Control, 25(7), 771–785. https://doi.org/10.1007/s10552-014-0377-3

4. Momenimovahed, Z., & Salehiniya, H. (2019). Epidemiological characteristics of and risk factors for breast cancer in the world. In Dove Medical Press Limited, Breast Cancer - Targets and Therapy (pp. 151–164) [Journal-article]. https://doi.org/10.2147/BCTT.S176070

5. Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P., & Zhu, H.-P. (n.d.). Risk factors and preventions of breast cancer. International Journal of Biological Sciences, 13, 1387–1397. https://doi.org/10.7150/ijbs.21635

6. Anampa, J., Makower, D., Sparano, J. A., & Anampa et al. (2015). Progress in adjuvant chemotherapy for breast cancer: an overview. In BMC Medicine [Journal-article]. https://doi.org/10.1186/s12916-015-0439-8

7. Hassan, M. S. U., Ansari, J., Spooner, D., Hussain, S. A., & Cancer Research UK. (2010). Chemotherapy for breast cancer. In ONCOLOGY REPORTS (Vols. 24–1121). https://doi.org/10.3892/or_0963

8. Wang, H., & Mao, X. (2020). Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer. Drug Design, Development and Therapy, 14, 2423–2433. https://doi.org/10.2147/DDDT.S253961

9. Balaji, K., Subramanian, B., Yadav, P., Radha, C. A., & Ramasubramanian, V. (2016). Radiation therapy for breast cancer: Literature review. Medical Dosimetry, 41(3), 253–257. https://doi.org/10.1016/j.meddos.2016.06.005

10. Haussmann, J., Corradini, S., Nestle-Kraemling, C., Bölke, E., Njanang, F. J. D., Tamaskovics, B., Orth, K., Ruckhaeberle, E., Fehm, T., Mohrmann, S., Simiantonakis, I., Budach, W., & Matuschek, C. (2020). Recent advances in radiotherapy of breast cancer. Radiation Oncology, 15(1). https://doi.org/10.1186/s13014-020-01501-x

11. Shah, C., a, Bauer-Nilsen, K., McNulty, R. H., Frank Vicini, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, & 21st Century Oncology, Michigan Healthcare Professionals, Farmington Hills, MI. (2020). Novel radiation therapy approaches for breast cancer treatment. In Seminars in Oncology [Journal-article]. https://doi.org/10.1053/j.seminoncol.2020.05.003

12. Burstein, H. J., Somerfield, M. R., Barton, D. L., ASCO, Dorris, A., Fallowfield, L. J., Jain, D., Johnston, S. R. D., Korde, L. A., Litton, J. K., Macrae, E. R., Peterson, L. L., Vikas, P., Yung, R. L., & Rugo, H. S. (2021). Endocrine treatment and targeted therapy for hormone Receptor–Positive, human Epidermal Growth Factor receptor 2–Negative metastatic breast cancer: ASCO Guideline update. In J Clin Oncol (Vol. 39, pp. 3959–3977). https://doi.org/10.1200/JCO.21.01392

13. Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., Manson, J. E., Stefanick, M. L., Pan, K., Barrington, W., Kuller, L. H., Simon, M. S., Lane, D., Johnson, K. C., Rohan, T. E., Gass, M. L. S., Cauley, J. A., Paskett, E. D., Sattari, M., & Prentice, R. L. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA, 324(4), 369. https://doi.org/10.1001/jama.2020.9482

14. Peddie, N., Agnew, S., Crawford, M., Dixon, D., MacPherson, I., & Fleming, L. (2021). The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis. The Breast, 58, 147–159. https://doi.org/10.1016/j.breast.2021.05.005

15. Barzaman, K., Moradi-Kalbolandi, S., Hosseinzadeh, A., Kazemi, M. H., Khorramdelazad, H., Safari, E., & Farahmand, L. (2021). Breast cancer immunotherapy: Current and novel approaches. International Immunopharmacology, 98, 107886. https://doi.org/10.1016/j.intimp.2021.107886:contentReference[oaicite:0]{index=0}.

16. Gagliato, D. de M., Buzaid, A. C., Perez-Garcia, J., & Cortes, J. (2020). Immunotherapy in breast cancer: Current practice and clinical challenges. BioDrugs. https://doi.org/10.1007/s40259-020-00436-9:contentReference[oaicite:1]{index=1}.

17. Henriques, B., Mendes, F., & Martins, D. (2021). Immunotherapy in breast cancer: When, how, and what challenges? Biomedicines, 9(11), 1687. https://doi.org/10.3390/biomedicines9111687:contentReference[oaicite:2]{index=2}.

18. Heil, J., Kuerer, H. M., Pfob, A., Rauch, G., Sinn, H. P., Golatta, M., Liefers, G. J., & Vrancken Peeters, M. J. (2020). Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: Current evidence and future challenges. Annals of Oncology, 31(1), 61-70. https://doi.org/10.1016/j.annonc.2019.10.012:contentReference[oaicite:0]{index=0}.

19. Riis, M. (2020). Modern surgical treatment of breast cancer. Annals of Medicine and Surgery, 56, 95-107. https://doi.org/10.1016/j.amsu.2020.06.016:contentReference[oaicite:1]{index=1}.

20. Magnoni, F., Galimberti, V., Corso, G., Intra, M., Sacchini, V., & Veronesi, P. (2020). Axillary surgery in breast cancer: An updated historical perspective. Seminars in Oncology. https://doi.org/10.1053/j.seminoncol.2020.09.001:contentReference[oaicite:2]{index=2}.

21. Barroso-Sousa, R., & Tolaney, S. M. (2021). Clinical development of new Antibody–Drug conjugates in Breast Cancer: to Infinity and Beyond. BioDrugs, 35(2), 159–174. https://doi.org/10.1007/s40259-021-00472-z

22. Corti, C., 1, Giugliano, F., 1, Nicolò, E., 1, Ascione, L., 1, & Giuseppe Curigliano. (2021). Antibody–Drug conjugates for the treatment of breast cancer. Cancers, 13, 2898. https://doi.org/10.3390/cancers13122898

23. Ferraro, E., Drago, J. Z., & Modi, S. (2021). Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Research, 23(1). https://doi.org/10.1186/s13058-021-01459-y

24. De Sousa Marcial, S. P., Carneiro, G., & Leite, E. A. (2017). Lipid-based nanoparticles as drug delivery system for paclitaxel in breast cancer treatment. Journal of Nanoparticle Research, 19(10). https://doi.org/10.1007/s11051-017-4042-0

25. Liyanage, P. Y., Hettiarachchi, S. D., Zhou, Y., Ouhtit, A., Seven, E. S., Department of Chemistry, University of Miami, Coral Gables, FL 33146, USA, Oztan, C. Y., Celik, E., Department of Aerospace and Mechanical Engineering, University of Miami, Coral Gables, FL 33146, USA, & Leblanc, R. M. (2019). Nanoparticle-mediated targeted drug delivery for breast cancer treatment. In BBA - Reviews on Cancer (pp. 419–433) [Journal-article]. Elsevier B.V. https://doi.org/10.1016/j.bbcan.2019.04.006

26. Mirza, Z., & Karim, S. (2019). Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges. Seminars in Cancer Biology, 69, 226–237. https://doi.org/10.1016/j.semcancer.2019.10.020

27. Alven, S., A., Nqoro, X., Buyana, B., & Blessing A. Aderibigbe. (2020). Polymer-Drug conjugate, a potential therapeutic to combat breast and lung cancer. In Pharmaceutics [Review]. https://doi.org/10.3390/pharmaceutics12050406

28. Juan, A., Cimas, F. J., Bravo, I., Pandiella, A., Ocaña, A., & Alonso-Moreno, C. (2020). An overview of antibody conjugated polymeric nanoparticles for breast cancer therapy. Pharmaceutics, 12(9), 802. https://doi.org/10.3390/pharmaceutics12090802

29. Wang, K., Guo, C., Dong, X., Yu, Y., Wang, B., Liu, W., & Chen, D. (2018). In vivo evaluation of Reduction-Responsive Alendronate-Hyaluronan-Curcumin Polymer-Drug conjugates for targeted therapy of bone metastatic breast cancer. Molecular Pharmaceutics, 15(7), 2764–2769. https://doi.org/10.1021/acs.molpharmaceut.8b00266

30. Abedin, M. R., Powers, K., Aiardo, R., Barua, D., Barua, S., Department of Chemical and Biochemical Engineering, Missouri University of Science and Technology, & Department of Electrical and Computer Engineering, Missouri University of Science and Technology. (2021). Antibody–drug nanoparticle induces synergistic treatment

efficacies in HER2 positive breast cancer cells. In Scientific Reports (Vol. 11, p. 7347) [Journal-article]. https://doi.org/10.1038/s41598-021-86762-6

31. Antibody conjugation of nanoparticles as therapeutics for breast cancer treatment. (2020). In International Journal of Molecular Sciences [Journal-article]. https://doi.org/10.3390/ijms21176018

32. Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer. (2010). In International Journal of Nanomedicine, International Journal of Nanomedicine (Vol. 5, pp. 445–454). https://www.dovepress.com/

33. Alven, S., A., Nqoro, X., Buyana, B., & Blessing A. Aderibigbe. (2020). Polymer-Drug conjugate, a potential therapeutic to combat breast and lung cancer. In Pharmaceutics [Review]. https://doi.org/10.3390/pharmaceutics12050406

34. Juan, A., Cimas, F. J., Bravo, I., Pandiella, A., Ocaña, A., & Alonso-Moreno, C. (2020). An overview of antibody conjugated polymeric nanoparticles for breast cancer therapy. Pharmaceutics, 12(9), 802. https://doi.org/10.3390/pharmaceutics12090802

35. Wang, K., Guo, C., Dong, X., Yu, Y., Wang, B., Liu, W., & Chen, D. (2018). In vivo evaluation of Reduction-Responsive Alendronate-Hyaluronan-Curcumin Polymer-Drug conjugates for targeted therapy of bone metastatic breast cancer. Molecular Pharmaceutics, 15(7), 2764–2769. https://doi.org/10.1021/acs.molpharmaceut.8b00266